12:00 AM
 | 
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GSK573719/vilanterol: Phase IIIa data

A 24-week, double-blind, international Phase IIIa trial in 872 COPD patients showed that once-daily 125/25 µg GSK573719/vilanterol met the co-primary endpoint of improving trough FEV1 from baseline to the end of treatment on day 169 vs. Spiriva HandiHaler tiotropium, but missed the co-primary endpoint of improving trough FEV1 from baseline to day 169 vs. 125 µg GSK573719 alone. Specifically, high-dose GSK573719/vilanterol improved trough FEV1 at day 169 by 74 mL compared to Spiriva (p=0.003) and by 37 mL compared to GSK573719 alone...

Read the full 396 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >